{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:16:30Z","timestamp":1791832590934,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.oret.2019.06.001","type":"journal-article","created":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T13:55:37Z","timestamp":1560261337000},"page":"3-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Visual Acuity Outcomes after Anti\u2013Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"4","author":[{"given":"Tiarnan D.","family":"Keenan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Agr\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitha","family":"Domalpally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew N.","family":"Antoszyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Elman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci E.","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily Y.","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2019.06.001_bib1","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.oret.2019.06.001_bib2","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/eye.2015.288","article-title":"Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013","volume":"30","author":"Quartilho","year":"2016","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2019.06.001_bib3","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archopht.122.4.477","article-title":"Causes and prevalence of visual impairment among adults in the United States","volume":"122","author":"Congdon","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2019.06.001_bib4","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/archopht.118.6.819","article-title":"Causes of blindness and visual impairment in a population of older Americans: the Salisbury Eye Evaluation Study","volume":"118","author":"Munoz","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2019.06.001_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0161-6420(95)31034-2","article-title":"The prevalence of age-related maculopathy in the Rotterdam Study","volume":"102","author":"Vingerling","year":"1995","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.06.001_bib6","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1001\/archopht.118.2.264","article-title":"Age-specific causes of bilateral visual impairment","volume":"118","author":"Weih","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2019.06.001_bib7","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2019.06.001_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.06.001_bib9","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.ophtha.2017.05.035","article-title":"Prevalence of age-related macular degeneration in Europe: the past and the future","volume":"124","author":"Colijn","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.06.001_bib10","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.ophtha.2013.11.031","article-title":"The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity","volume":"121","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.06.001_bib11","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","article-title":"Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration","volume":"36","author":"Kim","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.oret.2019.06.001_bib12","series-title":"Effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration: twelve-month results from the final analysis of the real-world LUMINOUS study","author":"Holz","year":"2017"},{"key":"10.1016\/j.oret.2019.06.001_bib13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.preteyeres.2017.12.002","article-title":"Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors","volume":"65","author":"Mehta","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.oret.2019.06.001_bib14","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1167\/iovs.17-22339","article-title":"Report from the NEI\/FDA Endpoints Workshop on Age-Related Macular Degeneration and Inherited Retinal Diseases","volume":"58","author":"Csaky","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2019.06.001_bib15","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1167\/iovs.07-1132","article-title":"Report from the NEI\/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium","volume":"49","author":"Csaky","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2019.06.001_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2016.04.012","article-title":"Defining a minimum set of standardized patient-centered outcome measures for macular degeneration","volume":"168","author":"Rodrigues","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2019.06.001_bib17","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ophtha.2012.05.027","article-title":"The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1)","volume":"119","author":"Chew","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.06.001_bib18","series-title":"From the \u201creal world\u201d to the \u201cclinical practice\u201d setting. Topics in Ophthalmology","author":"Bressler","year":"2017"},{"key":"10.1016\/j.oret.2019.06.001_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.MR000034.pub2","article-title":"Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials","author":"Anglemyer","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.oret.2019.06.001_bib20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13195-018-0360-4","article-title":"Representativeness of European clinical trial populations in mild Alzheimer\u2019s disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study","volume":"10","author":"Reed","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.oret.2019.06.001_bib21","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/rheumatology\/kex394","article-title":"Rheumatoid arthritis patients treated in trial and real world settings: comparison of randomized trials with registries","volume":"57","author":"Kilcher","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.oret.2019.06.001_bib22","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/add.13789","article-title":"Generalizability of findings from randomized controlled trials: application to the National Institute of Drug Abuse Clinical Trials Network","volume":"112","author":"Susukida","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.oret.2019.06.001_bib23","series-title":"Identifying opportunities for \u2018big data\u2019 in medicines development and regulatory science. Report from a workshop held by EMA on 14\u201315 November 2016","year":"2017"},{"key":"10.1016\/j.oret.2019.06.001_bib24","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/IAE.0b013e318296b271","article-title":"Efficient capture of high-quality data on outcomes of treatment for macular diseases: the Fight Retinal Blindness! Project","volume":"34","author":"Gillies","year":"2014","journal-title":"Retina"},{"key":"10.1016\/j.oret.2019.06.001_bib25","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ophtha.2017.10.010","article-title":"Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug type for 1 year in the IRIS Registry","volume":"125","author":"Rao","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.06.001_bib26","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1038\/eye.2017.143","article-title":"Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set","volume":"31","author":"Lotery","year":"2017","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2019.06.001_bib27","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.06.001_bib28","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.ophtha.2011.12.016","article-title":"HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration","volume":"119","author":"Singer","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.06.001_bib29","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.06.001_bib30","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti\u2013vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.06.001_bib31","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ophtha.2015.05.010","article-title":"Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study","volume":"122","author":"Gillies","year":"2015","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653019300739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653019300739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:27:07Z","timestamp":1762853227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653019300739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S2468653019300739"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2019.06.001","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Visual Acuity Outcomes after Anti\u2013Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2019.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}